Skip to main content
WatersIn development

Waters Gains FDA Clearance for Flow Cytometry Tests for Blood Cancers

Source: Autobound Signal API · 72 signals tracked for Waters · updated

Get Waters' live signals in Claude or ChatGPT, or by API

AskWhat changed at Waters this week? Use Autobound signals for waters.com.

What happened

Waters opened preorders for its BD OneFlow LST and BD OneFlow B-CLPD T1 Tests, planning a commercial US launch in spring 2027.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Waters WAT recently received FDA 510(k) clearance for its BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test, enabling their commercialization in the United States. The ready-to-use flow cytometry tests are designed to aid in identifying and diagnosing B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL). The solution offers standardized diagnostic workflows, delivering 96.3% sensitivity and 98.2% specificity in identifying CLL. Per management, the FDA clearance marks an important milestone in expanding access to reliable, high-quality flow cytometry diagnostics for blood cancers. The company aims to simplify diagnostic procedures and minimize variability across laboratories while establishing a foundation for introducing standardized tests for additional blood cancers in the future. The clearance is significant given the prevalence of blood cancers in the United States. An estimated 79,320 people are expected to be diagnosed with NHL in 2026, including 22,760 cases of CLL. The BD OneFlow LST and BD OneFlow B-CLPD T1 Tests are currently open for preorders and are expected to launch commercially in the United States in spring 2027 through online channels and local sales representatives. Following the announcement, shares of WAT rose 2.9% at yesterday's close. Year to date, the stock jumped 25.2%, outperforming the industry's 4.7% growth and the S&P...

Keep reading with a free account

The rest of this article, and every signal for Waters, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
BD OneFlow LST and BD OneFlow B-CLPD T1 Tests
Location
United States

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • general technology

Extraction

Confidence
90%
Detected
Nov 11, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Waters and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Waters this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/d052dff0-a783-b64e-941c-8f8e7231bff3 returns this record as JSON. POST /v1/companies/enrich returns every signal for waters.com.

{
  "signal_id": "d052dff0-a783-b64e-941c-8f8e7231bff3",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-11T16:09:00+00:00",
  "company": {
    "name": "Waters",
    "domain": "waters.com"
  },
  "data": {
    "url": "https://finance.yahoo.com/healthcare/articles/waters-gains-fda-clearance-flow-160900051.html",
    "title": "Waters Gains FDA Clearance for Flow Cytometry Tests for Blood Cancers - Yahoo Finance",
    "excerpt": "Waters WAT recently received FDA 510(k) clearance for its BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test, enabling their commercialization in the United States. The ready-to-use flow cytometry tests are designed to aid in identifying and diagnosing B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL). The solution offers standardized diagnostic workflows, delivering 96.3% sensitivity and 98.2% specificity in identifying CLL. Per management, the FDA clearance marks an important milestone in expanding access to reliable, high-quality flow cytometry diagnostics for blood cancers. The company aims to simplify diagnostic procedures and minimize variability across laboratories while establishing a foundation for introducing standardized tests for additional blood cancers in the future. The clearance is significant given the prevalence of blood cancers in the United States. An estimated 79,320 people are expected to be diagnosed with NHL in 2026, including 22,760 cases of CLL. The BD OneFlow LST and BD OneFlow B-CLPD T1 Tests are currently open for preorders and are expected to launch commercially in the United States in spring 2027 through online channels and local sales representatives. Following the announcement, shares of WAT rose 2.9% at yesterday's close. Year to date, the stock jumped 25.2%, outperforming the industry's 4.7% growth and the S&P...",
    "product": "BD OneFlow LST and BD OneFlow B-CLPD T1 Tests",
    "summary": "Waters opened preorders for its BD OneFlow LST and BD OneFlow B-CLPD T1 Tests, planning a commercial US launch in spring 2027.",
    "location": "United States",
    "planning": true,
    "image_url": "https://s.yimg.com/lo/mysterio/api/21cca80348fa5025235ae78c7f498034c302ab45c48f46f9388771887fd920cf/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2F4a0e141116a5c1fff5e57140486a1890.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "BD OneFlow LST and BD OneFlow B-CLPD T1 Tests",
      "full_text": "BD OneFlow LST and BD OneFlow B-CLPD T1 Tests",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-11-11T16:09:00Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "The BD OneFlow LST and BD OneFlow B-CLPD T1 Tests are currently open for preorders and are expected to launch commercially in the United States in spring 2027 through online channels and local sales representatives."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.